JP2011173850A - Stabilized panaxadiol composition - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a stabilized panaxadiol composition which stably contains panaxadiol having a physiological activity such as a sugar metabolism-improving action, further maintains the stability, and can simultaneously be stored for a long period. <P>SOLUTION: The stabilized panaxadiol composition is characterized by including at least panaxadiol [component (A)] and a panaxadiol-stabilizing agent [component (B)] comprising astaxanthin. <P>COPYRIGHT: (C)2011,JPO&INPIT

Description

  The present invention relates to a panaxadiol stabilizing composition that stably contains panaxadiol.

  Compounds belonging to danmaran triterpenes have various anti-cancer effects (see Patent Documents 1 and 2), anti-inflammatory actions against skin diseases (see Patent Document 3), and urinary albumin excretion suppressing effects (see Patent Document 4). It is known to have various physiological activities. In addition, the present inventors have previously found that panaxadiol, which is one of the compounds belonging to danmaran triterpenes, has an action of improving sugar metabolism.

  Panaxadiol is a sapogenin in which a sugar is detached from a plant-derived saponin (glycoside) and a side chain is closed. In the state of saponin, the absorption into the body is low, and since the sugar is absorbed after being broken down by intestinal bacteria, the effect varies depending on the individual, but sapogenin such as panaxadiol is bound to sugar. Therefore, minimization of the individual differences can be expected.

It is known that sapogenin can be easily produced by applying a strong acid aqueous solution to a saponin-containing plant and subjecting it to a hydrolysis treatment.
However, panaxadiol in the hydrolyzed product has a problem in that it is not stable as it is and is decomposed over time.

  The physiological activity of panaxadiol, particularly the glucose metabolism improving effect, does not appear immediately after ingesting panaxadiol, but a suitable glucose metabolism improving effect appears when ingested for a long period of time. Therefore, it is desired that panaxadiol can be stored stably for a long period of time, and a desired amount of panaxadiol can be taken as appropriate.

  Therefore, it is desired to provide a panaxadiol stabilizing composition that stably contains panaxadiol having physiological activity such as an action to improve sugar metabolism and that can be stored for a long period of time while maintaining its stability. Currently.

JP 2005-504799 A JP 58-57399 A JP 2007-008896 A JP-A-10-212296

  An object of the present invention is to solve the above-described problems and achieve the following objects. That is, the present invention provides a panaxadiol stabilizing composition that stably contains panaxadiol having physiological activity such as an action for improving sugar metabolism and that can be stored for a long period of time while maintaining its stability. Objective.

  In order to solve the above-mentioned problems, the present inventors have made extensive studies and as a result, obtained the following findings. That is, astaxanthin can suitably stabilize panaxadiol having physiological activities such as an action to improve sugar metabolism, and the panaxadiol stabilizing composition containing at least astaxanthin and panaxadiol is It was found that panaxadiol can be stored for a long time while maintaining the stability of panaxadiol, and the present invention has been completed.

The present invention is based on the above findings by the present inventors, and means for solving the above problems are as follows. That is,
<1> A panaxadiol stabilizing composition comprising at least panaxadiol (component (A)) and a panaxadiol stabilizer (component (B)) comprising astaxanthin.
<2> Panaxadiol (component (A)) is subjected to a hydrolysis treatment by applying a strong acid aqueous solution having a concentration of 0.01 mol / L to 4 mol / L to a saponin-containing plant, and the obtained hydrolysis treatment is performed. The panaxadiol stabilizing composition according to <1>, which is obtained by neutralizing the liquid, filtering, and drying the residue.
<3> The panaxadiol stabilization composition according to <2>, wherein the hydrolysis treatment is performed in the presence of a lower alcohol.
<4> After the hydrolysis treatment and before filtration, water is added to the solution after the hydrolysis treatment, and the lower alcohol concentration in the solution after the hydrolysis treatment is adjusted to 50% by volume or less. <2> to <3> The panaxadiol stabilizing composition according to any one of the above.
<5> The panaxadiol stabilization according to any one of <1> to <4>, wherein the content of the panaxadiol stabilizer (component (B)) is 0.05% by mass to 7% by mass. It is a composition.
<6> The mass ratio ((A) / (B)) between the content of panaxadiol (component (A)) and the content of panaxadiol stabilizer (component (B)) is 0.15. The panaxadiol stabilizing composition according to any one of <1> to <5>, which is ˜550.
<7> The panaxadiol stabilizing composition according to any one of <1> to <6>, wherein the composition is a food or drink.

  According to the present invention, the conventional problems can be solved, the object can be achieved, and panaxadiol having a physiological activity such as an action for improving sugar metabolism can be stably contained, and the stability thereof can be maintained. Thus, a panaxadiol stabilized composition that can be stored for a long period of time can be provided.

(Panaxadiol stabilizing composition)
The panaxadiol stabilizing composition of the present invention contains panaxadiol (component (A)) and a panaxadiol stabilizer (as component (B)) composed of astaxanthin. Contains the ingredients.

<(A) component>
Panaxadiol, which is the component (A), is a compound belonging to danmaran triterpenes represented by the following structural formula (1).
The component (A) is sapogenin in which sugar is detached from a plant-derived saponin (glycoside) and the side chain is closed.

<< Manufacturing method >>
There is no restriction | limiting in particular as a manufacturing method of the said (A) component, According to the objective, it can select suitably, For example, the method of obtaining from the plant containing a saponin, the method of synthesize | combining, etc. are mentioned. Commercial products can also be used. Among these, a method obtained from a plant containing saponin is preferable in that a highly safe panaxadiol stabilizing composition can be obtained, and a strong acid aqueous solution having a predetermined concentration is allowed to act on a plant containing saponin. After subjecting to hydrolysis treatment (hereinafter sometimes referred to as “hydrolysis treatment step”), the resulting hydrolyzed solution is neutralized (hereinafter also referred to as “neutralization step”). The method of filtering (hereinafter sometimes referred to as “filtering step”) and drying the residue (hereinafter sometimes referred to as “drying step”) contains a large amount of panaxadiol and is easily produced. It is more preferable in that it can be performed.

-Saponin-containing plants-
The saponin-containing plant used as a raw material for the panaxadiol is not particularly limited as long as it is a natural product containing saponin, and can be appropriately selected according to the purpose. Carrot Root, Araceae Tochibanin Ginseng Root (Carrot), Araliaceae Tochibaninjin Tochibaninjin Root (Chikusetininjin), Apiaceae Mishimasaiko Mishimasaiko Root (Psycho), Himehagi Himehagi Itohimegi Root (Onji) ), Himehagi genus Hiroha Senega Root (Senega), Rhizoaceae genus Kokikyo Root, cucurbitaceae genus Achachazul whole plant, leguminous licorice licorice root, Amaranthaceae genus Inokozuchi hinata nokozuchi root Akebiaceae genus Apis mellifera stems, black crow Doki School Natsume genus jujube fruit of the (gymnastics), Liliaceae Anemarrhenae asphodeloides genus Anemarrhenae asphodeloides of rhizome (Chimo), Liliaceae ophiopogon Ophiopogon root (Bakumondou), and the like dioscoreaceae Dioscorea Onidokoro of rhizome (explicit solution). These may be used alone or in combination of two or more.

  The saponin-containing plant may be used as it is collected from nature, for example, by using it after pretreatment appropriately combining washing, drying, cutting, crushing, pulverization, etc. It becomes possible to perform the hydrolysis treatment described later more efficiently. Among these, it is preferable to use a pulverized powdery plant as the saponin-containing plant. In addition, you may utilize a commercial item for the said saponin containing plant.

-Hydrolysis treatment process-
In the hydrolysis treatment step, the saponin-containing plant is reacted with a strong acid aqueous solution having a predetermined concentration to hydrolyze the saponin in the plant, and the component (A) is a sapogenin that is more absorbable in the body than saponin. Is a step of generating.

The strong acid aqueous solution is not particularly limited as long as it is an aqueous solution containing a strong acid, and can be appropriately selected according to the purpose. For example, an aqueous solution containing an inorganic acid such as hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid is preferable. These may be used alone or in combination of two or more. Among these, an aqueous solution containing hydrochloric acid is more preferable.
There is no restriction | limiting in particular as a density | concentration of the acid in the said strong acid aqueous solution, Although it can select suitably according to the objective, 0.01 mol / L-4 mol / L are preferable, and 0.5 mol / L-3 mol / L are more preferable. If the acid concentration is less than 0.01 mol / L, hydrolysis may be insufficient and the component (A) may not be efficiently produced. If it exceeds 4 mol / L, hydrolysis may proceed excessively. Yes, and uneconomical. On the other hand, when the concentration of the acid is within the preferred range, the component (A) can be efficiently produced by sufficient hydrolysis.

  There is no restriction | limiting in particular as the usage-amount of the said strong acid aqueous solution, Although it can select suitably according to the objective, It is preferable to use 2 to 20 times volume with respect to the said saponin containing plant. When the amount of the strong acid aqueous solution used is less than 2 times the volume of the saponin-containing plant, the saponin-containing plant may not be sufficiently immersed and the hydrolysis treatment may be insufficient. The reaction is saturated and uneconomical.

--Lower alcohol--
The hydrolysis treatment is more preferably performed in the presence of a lower alcohol. By using a lower alcohol in the hydrolysis step, the affinity between the saponin-containing plant and the strong acid aqueous solution can be improved, and the hydrolysis can proceed efficiently.
In addition, the use of the lower alcohol is advantageous in that the taste and handleability of the obtained component (A) can be improved.
There is no restriction | limiting in particular as said lower alcohol, According to the objective, it can select suitably, For example, C1-C5 alcohol etc. are mentioned. These may be used alone or in combination of two or more. Among these, methanol, ethanol, and propanol are preferable, and ethanol is particularly preferable from the viewpoint of safety.

There is no restriction | limiting in particular as the usage-amount of the said lower alcohol, Although it can select suitably according to the objective, 1 volume%-80 volume% are preferable with respect to the total amount of a hydrolysis liquid, 10 volume%-50 volume % Is more preferable, and 20% by volume to 40% by volume is more preferable. When the amount of the lower alcohol used is less than 1% by volume with respect to the total amount of the hydrolyzed solution, the component (A) may not be efficiently produced. Often, the component (A) cannot be produced and is uneconomical. On the other hand, when the amount of the lower alcohol used is within the more preferable range, it is advantageous in that the component (A) can be efficiently produced.
The “total amount of hydrolyzed liquid” refers to the total amount of the reaction liquid including the strong acid aqueous solution and the lower alcohol.

  The total amount of the reaction solution (total amount of hydrolysis solution) including the strong acid aqueous solution and the lower alcohol is preferably 2 to 20 times the volume of the saponin-containing plant. When the total reaction liquid amount is less than 2 times the volume of the saponin-containing plant, the saponin-containing plant may not be sufficiently immersed and the hydrolysis treatment may be insufficient. The reaction is saturated and uneconomical.

  There is no restriction | limiting in particular as processing temperature in the said hydrolysis process, Although it can select suitably according to the objective, 60 to 100 degreeC is preferable and 70 to 90 degreeC is more preferable. If the treatment temperature is less than 60 ° C, hydrolysis may be insufficient and the component (A) may not be efficiently produced. If the treatment temperature exceeds 100 ° C, special production equipment is required. It is an economy. On the other hand, when the treatment temperature is within the more preferable range, it is advantageous in that the component (A) can be efficiently generated.

  There is no restriction | limiting in particular as processing time in the said hydrolysis process, Although it can select suitably according to the objective, 30 minutes-24 hours are preferable, and 2 hours-8 hours are more preferable. If the treatment time is less than 30 minutes, hydrolysis may be insufficient and the component (A) may not be efficiently produced. If the treatment time exceeds 24 hours, the reaction may proceed excessively. It is uneconomical. On the other hand, when the processing time is within the more preferable range, it is advantageous in that the component (A) can be efficiently generated.

-Neutralization process-
The neutralization step is a step of neutralizing the hydrolyzed liquid obtained in the hydrolysis step.
The neutralization method is not particularly limited and may be appropriately selected from known methods according to the purpose. For example, the hydrolyzed solution may contain sodium hydroxide, potassium hydroxide, or the like. It can be carried out by appropriately adding a strong base aqueous solution.
The pH after neutralization is not particularly limited as long as it is neutral, and can be appropriately selected according to the purpose, but is preferably 5 to 8.

-Filtration process-
The said filtration process is a process of filtering the liquid after the hydrolysis process after neutralizing in the said neutralization process, and isolate | separating into a filtrate and a residue.
There is no restriction | limiting in particular as said filtration method, According to the objective, it can select suitably from well-known methods.
After filtration, washing with water may be repeated until there is no more salt.

--Hydrofiltration--
When the lower alcohol is not used in the hydrolysis treatment step, the neutralization can proceed to the filtration step as it is. However, when the lower alcohol is used, the produced (A) is produced before the filtration. In order to promote the residue of the components in the residue, it is preferable to add water to lower the lower alcohol concentration in the liquid after the hydrolysis treatment.
In this case, the larger the amount of water added, the better. However, the lower alcohol concentration in the solution after the hydrolysis treatment is preferably as low as possible. Specifically, it is preferably added so as to be 50% by volume or less. It is more preferable to add so that it may become volume% or less, and it is still more preferable to add so that it may become 10 volume% or less. If the lower alcohol concentration in the liquid after the hydrolysis treatment is subjected to filtration while exceeding 50% by volume, the produced component (A) is dissolved in the lower alcohol and discharged as a filtrate. The sapogenin content of may decrease. On the other hand, when the lower alcohol concentration in the liquid after the hydrolysis treatment is within the further preferable range, it is advantageous in that the content of the component (A) in the residue can be further increased.

-Drying process-
The said drying process is a process of drying the residue after the said filtration process, and obtaining the dried material of the said (A) component.
The method for performing the drying is not particularly limited and can be appropriately selected from known methods according to the purpose. Examples thereof include a freeze-drying method, a ventilation drying method, a heat drying method, and a vacuum drying method. It is done.

  The component (A) obtained by hydrolyzing the saponin-containing plant with a strong acid aqueous solution may be used as a dried powder, suspended in a solution such as water or ethanol, and further desired. However, it is preferable to use the powder as it is because the panaxadiol-stabilized composition can be easily produced.

-Content-
There is no restriction | limiting in particular as content of the said (A) component in the said panaxadiol stabilization composition, According to the objective, it can select suitably, Although it is so preferable that it is many, 0.1 mass% or more is preferable. 1 mass% or more is more preferable, 3 mass% or more is further more preferable, and 5 mass% or more is especially preferable.

-Decomposition rate-
In the panaxadiol stabilizing composition, the decomposition rate of the component (A) is the initial content of the content of the component (A) (panaxadiol) in the panaxadiol stabilizing composition immediately after production. ) Component amount ", and the content of panaxadiol after being allowed to stand for an appropriate time is" after storage (A) component amount ", it can be calculated by the following formula.
Decomposition rate (%) = (initial (A) component amount−after storage (A) component amount) / initial (A) component amount × 100

  There is no restriction | limiting in particular as said decomposition rate, Although it can select suitably according to the objective, 12% or less is preferable. 9.1% or less is more preferable, and 2% or less is still more preferable.

  The component (A) obtained by hydrolyzing the saponin-containing plant using a strong acid aqueous solution has a problem that it is poor in stability and decomposes over time. The all-stabilized composition is advantageous in that the stability of the component (A) obtained by the hydrolysis treatment can be improved.

<(B) component>
The panaxadiol stabilizer which is the component (B) is composed of astaxanthin. Astaxanthin is a compound (CAS number: 472-61-7) represented by the following structural formula (2), has an antioxidant action, and is blended for the purpose of stabilizing the component (A).

  Astaxanthin has a general property of a hydrophobic compound having a melting point of 215 ° C. to 216 ° C., easily soluble in chloroform, and hardly soluble in ethanol, acetone, ethyl acetate, and water. Further, in general, an antioxidant action, an anti-inflammatory action, an arteriosclerosis inhibiting action and the like are known, and the antioxidant action is known to be about 1,000 times that of vitamin E.

  There is no restriction | limiting in particular as content of the said (B) component in the said panaxadiol stabilization composition, Although it can select suitably according to the objective, 0.05 mass%-5 mass% are preferable, 1 mass%-5 mass% are more preferable. When the component (B) is less than 0.05% by mass, the stabilizing action of the component (A) may be insufficient. Moreover, when the said (B) component exceeds 5 mass%, since astaxanthin is expensive, it is uneconomical. Moreover, even if it mix | blends exceeding 5 mass%, since the stabilization effect | action of the said (A) component may be saturated, a sufficient stabilization effect | action can be acquired at 5 mass% at most.

<(A) / (B) (component)>
There is no restriction | limiting in particular as mass ratio ((A) / (B)) of content of the said (A) component, and content of the said (B) component, Although it can select suitably according to the objective. 0.15-550 are preferable, 0.8-110 are more preferable, and 1.0-5.2 are still more preferable.
When the mass ratio (A) / (B) exceeds 550, the component (A) may not be sufficiently stabilized.

<Other ingredients>
The other components are not particularly limited and may be appropriately selected depending on the purpose. Examples thereof include pharmacologically acceptable carriers and auxiliary ingredients or additives used for food and drink. It is done.

-Auxiliary raw materials or additives-
The auxiliary raw material or additive is not particularly limited and may be appropriately selected depending on the intended purpose. For example, glucose, fructose, sucrose, maltose, sorbitol, stevioside, rubusoside, corn syrup, lactose, citric acid , Tartaric acid, malic acid, succinic acid, lactic acid, L-ascorbic acid, dl-α-tocopherol, sodium erythorbate, glycerin, propylene glycol, glycerin fatty acid ester, polyglycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, Arabia Examples include gum, carrageenan, casein, gelatin, pectin, agar, vitamin Bs, nicotinic acid amide, calcium pantothenate, amino acids, calcium salts, pigments, fragrances, preservatives and the like.
There is no restriction | limiting in particular as content of the said other component, According to the objective, it can select suitably.

<< Food & Drink >>
The panaxadiol stabilizing composition is preferably a food or drink. Moreover, the said panaxadiol stabilization composition may be used as a food-drinks raw material, and may be contained in a known food-drinks.
Here, the food and drink are those which are less likely to harm human health and are taken by oral or gastrointestinal administration in normal social life. It is not limited to the category of goods, etc., and means, for example, a wide range of foods that are taken orally, such as general foods, health foods, health functional foods, quasi drugs, and pharmaceuticals.

-Types of food and drink-
There is no restriction | limiting in particular as said kind of food / beverage products, It can select suitably according to the objective, For example, drinks, such as a soft drink, a carbonated drink, a nutrition drink, a fruit drink, a lactic acid drink; Ice cream, ice sherbet, Frozen confectionery such as shaved ice; noodles such as buckwheat, udon, harusame, gyoza skin, sushi mai, Chinese noodles, instant noodles; rice cake, candy, gum, chocolate, tablet confectionery, snack confectionery, biscuits, jelly, jam, cream, baked Sweets such as confectionery and bread; crab, salmon, clams, tuna, sardines, shrimp, skipjack, mackerel, whale, oyster, saury, squid, red scallop, scallop, abalone, sea urchin, salmon roe, tocobushi, etc .; Processed fishery and livestock products such as sausages; dairy products such as processed milk and fermented milk; salad oil, tempura oil, margarine, mayonnaise, chocolate Oil and fat processed foods such as toning, whipped cream and dressing; seasonings such as sauces and sauces; curry, stew, oyakodon, rice bowl, miscellaneous cooking, Chinese rice bowl, and rice bowl, tempura, eel rice, hayashi rice, oden, marvodorf, Retort pouch foods such as beef bowl, meat sauce, egg soup, omelet rice, dumplings, shumai, hamburg, meatballs; various forms of health foods, nutritional supplements, pharmaceuticals, quasi drugs and the like.

<Manufacturing method>
There is no restriction | limiting in particular as a manufacturing method of the said panaxadiol stabilization composition, According to the objective, it can select suitably, For example, the said (A) component and the said (B) component, Furthermore, if necessary, the said Examples include a method of mixing other components.
There is no restriction | limiting in particular as a property of the said panaxadiol stabilization composition, Although it can select suitably according to the objective, The state of the dry powder is preferable at the point which can maintain storage stability.

<Dosage form>
When the panaxadiol stabilizing composition is used as various forms of health foods, dietary supplements, pharmaceuticals, quasi drugs, etc., the dosage form is not particularly limited and is appropriately selected according to the purpose. Examples thereof include oral solid preparations, oral semisolid preparations, and oral liquid preparations.

-Oral solid agent-
The oral solid preparation is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include tablets, coated tablets, granules, powders, capsules, troches, tablets and the like.
There is no restriction | limiting in particular as a manufacturing method of the said oral solid preparation, A normal method can be used, for example, the said (A) component and the said (B) component, Furthermore, the said other component, various, as needed It can be produced by adding an excipient to the additive.
The excipient is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include lactose, sucrose, sodium chloride, glucose, starch, calcium carbonate, kaolin, microcrystalline cellulose, and silicic acid. .
There is no restriction | limiting in particular as said additive, According to the objective, it can select suitably, For example, a binder, a disintegrating agent, a lubricant, a coloring agent, a flavoring / flavoring agent etc. are mentioned.

The binder is not particularly limited and may be appropriately selected depending on the intended purpose. For example, water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethylcellulose, hydroxypropylcellulose, hydroxy Examples include propyl starch, methyl cellulose, ethyl cellulose, shellac, calcium phosphate, and polyvinyl pyrrolidone.
The disintegrant is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include dry starch, sodium alginate, agar powder, sodium bicarbonate, calcium carbonate, sodium lauryl sulfate, stearic acid monoglyceride, and lactose. Is mentioned.
The lubricant is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include purified talc, stearate, borax, and polyethylene glycol.
The colorant is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include titanium oxide and iron oxide.
The flavoring / flavoring agent is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include sucrose, orange peel, citric acid, and tartaric acid.

-Oral semi-solid formulation-
The oral half-solid preparation is not particularly limited as long as it is located between the liquid preparation and the solid preparation, and can be appropriately selected according to the purpose. For example, a lozenge, chewing gum, whipping agent, jelly Agents and the like.
There is no restriction | limiting in particular as a manufacturing method of the said oral semi-solid preparation, A normal method can be used, For example, the said (A) component and the said (B) component, Furthermore, as needed, said other component It can be produced by adding a gelling agent, a thickener, a stabilizer and the like.

There is no restriction | limiting in particular as said gelling agent, According to the objective, it can select suitably, For example, agar, gelatin, starch, gellan etc. are mentioned.
The thickener is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include xanthan, carrageenan, locust, guar, tamarind, and pectin.
There is no restriction | limiting in particular as said stabilizer, According to the objective, it can select suitably, For example, tragacanth, gum arabic, gati gum etc. are mentioned.

-Oral solution-
There is no restriction | limiting in particular as said oral liquid agent, According to the objective, it can select suitably, For example, an internal use liquid agent, a syrup agent, an elixir etc. are mentioned.
There is no restriction | limiting in particular as a manufacturing method of the said oral liquid preparation, A normal method can be used, for example, it adds to the said (A) component and the said (B) component, and also the said other component as needed. It can be manufactured by adding an agent.
There is no restriction | limiting in particular as said additive, According to the objective, it can select suitably, For example, a flavoring / flavoring agent, a buffering agent, a stabilizer, etc. are mentioned.

The flavoring / flavoring agent is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include sucrose, orange peel, citric acid, and tartaric acid.
There is no restriction | limiting in particular as said buffering agent, According to the objective, it can select suitably, For example, sodium citrate etc. are mentioned.
There is no restriction | limiting in particular as said stabilizer, According to the objective, it can select suitably, For example, tragacanth, gum arabic, gelatin, etc. are mentioned.

<Ingestion>
There is no restriction | limiting in particular as an ingestion method, ingestion amount, ingestion time, and ingestion object of the said panaxadiol stabilization composition, According to the objective, it can select suitably.
The intake amount is not particularly limited and may be appropriately selected in consideration of various factors such as the age, weight, constitution, symptom, and presence / absence of administration of a drug containing another component as an active ingredient. it can.
The animal species to be ingested are those that are suitably applied to humans, but as long as their effects are exerted, animals other than humans (eg, mice, rats, hamsters, birds, dogs, Cats, sheep, goats, cows, pigs, monkeys, etc.).

<Application>
The panaxadiol stabilizing composition stably contains panaxadiol having physiological activities such as an action for improving sugar metabolism, and can be stored for a long period of time while maintaining its stability. It can be suitably used as a food or drink.

  EXAMPLES The present invention will be specifically described below with reference to examples and comparative examples of the present invention, but the present invention is not limited to these examples.

(Production Example 1)
Suspended 100 g of Tanachi powder (manufactured by Matsuura Pharmaceutical Co., Ltd.) in 1 L of 5.9 vol% hydrochloric acid (1.92 mol / L hydrochloric acid hydrolyzate) containing 25 vol% ethanol, and while stirring slowly, 80 The mixture was heated at 0 ° C. for 6 hours to perform a hydrolysis treatment. The obtained hydrolyzed solution was cooled on ice, and adjusted to pH 7.0 by adding 5M aqueous sodium hydroxide solution. Subsequently, after diluting 10 times with distilled water and filtering with suction, the residue was freeze-dried to obtain 18 g of acid-treated product of Tabashichi powder. When this acid-treated product was used to measure the content of panaxadiol (PD) by the measurement method described later, the content of panaxadiol (hereinafter sometimes referred to as “PD”) was 5.5 mass. %Met.

(Production Example 2)
Suspend 100 g of ginseng powder (manufactured by Matsuura Pharmaceutical Co., Ltd.) in 1 L of 5.9 vol% hydrochloric acid (1.92 mol / L hydrochloric acid hydrolyzate) and heat at 80 ° C. for 6 hours with gentle stirring. Then, hydrolysis treatment was performed. The obtained hydrolyzed solution was cooled on ice, and adjusted to pH 7.0 by adding 5M aqueous sodium hydroxide solution. Next, after suction filtration, the residue was dried by warm ventilation to obtain 15 g of acid-treated product of rice cake powder. When this acid-treated product was used to measure the content of panaxadiol (PD) by the measurement method described later, the content of panaxadiol (PD) was 3.6% by mass.

(Production Example 3)
Suspend 100 g of Tanachi powder (manufactured by Matsuura Pharmaceutical Co., Ltd.) in 1 L of 5.0 volume% sulfuric acid (sulfuric acid hydrolyzate with a concentration of 0.94 mol / L) containing 25 volume% ethanol and slowly stir 80 The mixture was heated at 0 ° C. for 6 hours to perform a hydrolysis treatment. The obtained hydrolyzed solution was cooled on ice, and adjusted to pH 7.0 by adding 5M aqueous sodium hydroxide solution. Subsequently, after diluting 10 times with distilled water and filtering with suction, the residue was freeze-dried to obtain 16 g of acid-treated product of Tabashichi powder. When this acid-treated product was used to measure the content of panaxadiol (PD) by the measurement method described later, the content of panaxadiol (PD) was 5.2% by mass.

(Production Example 4)
Suspend 100 g of ginseng (manufactured by Matsuura Pharmaceutical Co., Ltd.) in 1 L of 5.9 vol% hydrochloric acid (1.92 mol / L hydrochloric acid hydrolyzate) containing 25 vol% ethanol and slowly stir 80 The mixture was heated at 0 ° C. for 6 hours to perform a hydrolysis treatment. The obtained hydrolyzed solution was cooled on ice, and adjusted to pH 7.0 by adding 5M aqueous sodium hydroxide solution. Subsequently, after diluting 10 times with distilled water and filtering with suction, the residue was freeze-dried to obtain 16 g of acid-treated product of Tabashichi powder. When this acid-treated product was used to measure the content of panaxadiol (PD) by the measurement method described later, the content of panaxadiol (PD) was 3.0% by mass.

(Production Example 5)
Suspend 100 g of rice powder (manufactured by Matsuura Pharmaceutical Co., Ltd.) in 1 L of 0.031 vol% hydrochloric acid (0.01 mol / L hydrochloric acid hydrolyzate) containing 25 vol% ethanol and slowly stir 90 The mixture was heated at 0 ° C. for 24 hours to perform a hydrolysis treatment. The obtained hydrolyzed solution was cooled on ice, and adjusted to pH 7.0 by adding 5M aqueous sodium hydroxide solution. Subsequently, after diluting 10 times with distilled water and filtering with suction, the residue was freeze-dried to obtain 18 g of acid-treated product of Tabashichi powder. When this acid-treated product was used to measure the content of panaxadiol (PD) by the measurement method described later, the content of panaxadiol (PD) was 0.15% by mass.

(Production Example 6)
Suspend 100 g of Tanachi powder (manufactured by Matsuura Pharmaceutical Co., Ltd.) in 1 L of 12.3% by volume hydrochloric acid (4.0 mol / L hydrochloric acid hydrolyzate) containing 25% by volume of ethanol, and slowly stir 80%. The mixture was heated at 0 ° C. for 6 hours to perform a hydrolysis treatment. The obtained hydrolyzed solution was cooled on ice, and adjusted to pH 7.0 by adding 5M aqueous sodium hydroxide solution. Subsequently, after diluting 10 times with distilled water and filtering with suction, the residue was freeze-dried to obtain 16 g of acid-treated product of Tabashichi powder. When this acid-treated product was used to measure the content of panaxadiol (PD) by the measurement method described later, the content of panaxadiol (PD) was 3.5% by mass.

(Production Example 7)
Suspend 100 g of Tanachi powder (manufactured by Matsuura Pharmaceutical Co., Ltd.) in 1 L of 5.9 vol% hydrochloric acid (1.92 mol / L hydrochloric acid hydrolyzate) containing 80 vol% ethanol, and slowly stir 80 The mixture was heated at 0 ° C. for 6 hours to perform a hydrolysis treatment. The obtained hydrolyzed solution was cooled on ice, and adjusted to pH 7.0 by adding 5M aqueous sodium hydroxide solution. Next, 0.6 L of distilled water was added and suction filtered, and then the residue was freeze-dried to obtain 13 g of acid-treated product of Tabashichi powder. When this acid-treated product was used to measure the content of panaxadiol (PD) by the measurement method described later, the content of panaxadiol (PD) was 1.6% by mass.

  The production conditions and panaxadiol (PD) content of Production Examples 1 to 7 are summarized in Tables 1 and 2.

<Measurement of Panaxadiol (PD) Content>
The method for measuring the content of panaxadiol (PD) in the acid-treated products of Production Examples 1 to 7 is as follows.
About 0.1 g of the acid-treated product of Production Examples 1 to 7 was accurately weighed, added with about 8 mL of ethanol (purity 99.5% by mass), and suspended for 15 minutes using an ultrasonic bath. After centrifugation at about 700 × g for 10 minutes, ethanol (purity 99.5% by mass) was added to the supernatant to make exactly 10 mL. This liquid was measured by gas chromatography under the following conditions. The retention time of panaxadiol (PD) under the following conditions was about 18 minutes.
-GC measurement conditions-
Gas chromatograph: GC353B manufactured by GL Sciences Inc.
Detector: Hydrogen flame ionization detector (FID)
Injection method: Split injection method (split ratio 1:50)
Column: DB-17MS manufactured by J & W (length 30 m, inner diameter 0.25 mm, film thickness 0.25 μm)
Column temperature: Initial temperature: 310 ° C
Initial temperature holding time: 20 minutes
Temperature increase rate: 10 ° C / min
Achieving temperature: 320 ° C
Achieving temperature holding time: 14 minutes Carrier gas: Helium Flow rate: 1.5 mL / min Inlet temperature: 320 ° C
Detector temperature: 320 ° C
Injection volume: 1 μL

(Examples 1-12)
Astaxanthin (manufactured by Wako Pure Chemical Industries, Ltd.) was added to 9 g of the acid-treated product of Production Examples 1 to 7 according to the blending amount (mass%) shown in Tables 3 to 11, and mixed in a mortar. This was put into a brown glass bottle with a screw cap and stored at 40 ° C. for 3 months, and then the content of panaxadiol (PD) was measured by gas chromatography in the same manner as in Production Examples 1-7. The results are shown in Tables 3-11.

(Comparative Examples 1, 14, 19, 24, 29, 34, and 39)
10 g of the acid-treated product of Production Examples 1 to 7 is put in a brown glass bottle with a screw cap, stored at 40 ° C. for 3 months, and then subjected to panaxadiol (PD) by gas chromatography in the same manner as in Production Examples 1 to 7. The content of was measured. The results are shown in Tables 4-11.

(Comparative Examples 2-13, 15-18, 20-23, 25-28, 30-33, 35-38, and 40-43)
In 9 g of the acid-treated product of Production Examples 1 to 7, (+)-catechin hydrate (manufactured by Wako Pure Chemical Industries, Ltd.), ethylenediaminetetraacetic acid (two Sodium salt, dihydrate) (EDTA: Wako Pure Chemical Industries, Ltd.), D-(-)-mannitol (Wako Pure Chemical Industries, Ltd.), and sodium sulfite (anhydrous) (Wako Pure Chemical Industries, Ltd.) (Hereinafter, these comparative components may be referred to as “component (B ′)”) and mixed in a mortar. This was put into a brown glass bottle with a screw cap and stored at 40 ° C. for 3 months, and then the content of panaxadiol (PD) was measured by gas chromatography in the same manner as in Production Examples 1-7. The results are shown in Tables 4-11.

<Decomposition rate of panaxadiol (PD)>
Panaxadi (PD) content in the acid-treated products of Production Examples 1 to 7 was defined as “initial PD amount”, and Panaxazi after storage for 3 months at 40 ° C. in Examples 1 to 12 and Comparative Examples 1 to 43 When the content of all (PD) was “PD amount after storage”, the decomposition rate (%) of panaxadiol (PD) was calculated by the following formula. The decomposition rate was set to 12% or less. The results are also shown in Tables 4 to 11.
Decomposition rate (%) = (initial PD amount−PD amount after storage) / initial PD amount × 100

As shown in Tables 3 to 11, the storage stability is improved by adding astaxanthin to the acid-treated product of Tanashi powder or Ginseng that contains a high amount of panaxadiol (PD), which is suitable for food and drink. It turns out that it is available.
Astaxanthin is known as an antioxidant, but panaxadiol (PD) is not known in detail because no improvement in stability was observed when mixed with other antioxidant compounds. However, it is surmised that the stabilization of the panaxadiol is not caused solely by the antioxidant action of astaxanthin.

  The panaxadiol stabilizing composition of the present invention stably contains panaxadiol having physiological activities such as an action to improve sugar metabolism, and can be stored for a long time while maintaining its stability. Therefore, it can be suitably used as a food or drink.

Claims (4)

  A panaxadiol stabilizing composition comprising at least panaxadiol (component (A)) and a panaxadiol stabilizer (component (B)) comprising astaxanthin.   The panaxadiol stabilizing composition according to claim 1, wherein the content of the panaxadiol stabilizer (component (B)) is 0.05% by mass to 7% by mass.   The mass ratio ((A) / (B)) between the content of panaxadiol (component (A)) and the content of panaxadiol stabilizer (component (B)) is 0.15 to 550. The panaxadiol stabilizing composition according to any one of claims 1 to 2.   The panaxadiol stabilizing composition according to any one of claims 1 to 3, which is a food or drink.